Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico
The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [<29 and 29-32...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Salud Pública de México |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Instituto Nacional de Salud Pública
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://www.redalyc.org/articulo.oa?id=10623032007 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|